In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …

Tumor‐infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cells have
demonstrated remarkable success in the treatment of relapsed/refractory melanoma and …

Lack of biopsies after treatment, especially in solid tumors, restricts the understanding of
chimeric antigen receptor (CAR)-T cells-related characteristic in vivo, thus hindering the …

Background Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor
prognosis. Current treatment options are limited and often ineffective. CAR T cell therapy …

The excessive cytokine release and limited persistence represent major challenges for
chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs …

Chimeric antigen receptor (CAR) T‐cell therapy demonstrates efficacy for the treatment of
hematologic cancers, but remains challenging in solid tumors because of the hostile tumor …

Unlocking the potential of broadly reactive coronavirus monoclonal antibodies (mAbs) and
their derivatives offers a transformative therapeutic avenue against severe COVID-19 …

Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients
with B-cell malignancies and multiple myeloma, they continue to have limited efficacy …

Chimeric antigen receptor (CAR)-T cell therapy yields good results in the treatment of
various hematologic malignancies. However, the efficacy of CAR-T cell therapy against solid …

The success of chimeric antigen receptor (CAR) T cells in blood cancers has intensified
efforts to develop CAR T therapies for solid cancers. In the solid tumor microenvironment …